Reimbursed Care Access in South Sudan

Currently classified as a strictly controlled substance under international drug control conventions and, in South Sudan, there is no public record of national medical authorization or reimbursement for psilocybin outside of approved clinical research. International scheduling: psilocybin (and psilocin) are listed under international drug control conventions which limit use to medical and scientific purposes; national authorities typically follow these schedules. #.

Currently classified as a strictly controlled substance under national drug scheduling laws in line with the 1971 UN Convention (MDMA is listed in Schedule I of the 1971 Convention), with no authorized medical use or reimbursement in South Sudan outside of approved clinical research. There is no publicly available evidence of MDMA registration, compassionate‑use policy, or reimbursement by South Sudan’s Ministry of Health. # #.

There is no public record of national regulatory approval, reimbursement, or a named esketamine (Spravato) program in South Sudan; novel branded intranasal esketamine products approved in high‑income jurisdictions are not listed in publicly available South Sudan national medicine listings or policy documents. Ketamine (racemate) is included on the WHO Model List of Essential Medicines and is used as an anaesthetic agent in South Sudan, but esketamine as a distinct, regulated antidepressant product (e.g., Spravato) has no documented national approval or reimbursement pathway. South Sudan’s Ministry of Health and WHO country materials discuss a new national pharmaceutical policy and focus on essential medicines and supply chain strengthening but do not indicate licensed esketamine programs or public reimbursement schemes. # #

Ketamine (racemic) is recognized and used in South Sudan primarily as an essential injectable anaesthetic and analgesic agent; it appears on the WHO Model List of Essential Medicines and is supplied to South Sudan health facilities via national and partner‑led essential medicines programs, but there is no evidence of a nationally funded, structured reimbursement program for ketamine when used for psychiatric indications (e.g., treatment‑resistant depression). Clinical/operational context: ketamine is listed by WHO as an essential injectable anaesthetic and is included in international guidance for anaesthesia and emergency care; South Sudan’s Ministry of Health has received and managed consignments of essential medicines via WHO supply chains and has a 2022 Pharmaceutical Policy and Strategy aimed at strengthening medicines governance and availability—this is the basis for ketamine’s clinical presence in the country for anaesthesia and emergency use, but psychiatric use and any reimbursement for such indications appear undocumented. Availability and affordability: surveys and evaluations of Juba County and other South Sudan health services emphasize very limited availability of many essential medicines and weak public provision, meaning that even WHO‑listed medicines can be intermittently available; private purchase is common when public stocks are absent. Reimbursement and payer environment: South Sudan lacks a mature national public insurance reimbursement system for pharmaceuticals; medicines are often supplied through donor, humanitarian, or out‑of‑pocket mechanisms rather than universal government reimbursement. # # #

Currently classified as a strictly controlled substance under the 1971 UN Convention (DMT is listed in Schedule I of the 1971 Convention) and therefore subject to tight controls; there is no evidence of national authorization, medical registration, or reimbursement for DMT or DMT‑containing preparations in South Sudan outside of approved research. Natural plant preparations containing DMT (e.g., ayahuasca) are treated variably worldwide, but South Sudan has no documented legal carve‑outs or traditional‑use exceptions in public regulatory materials. # #

Currently classified as a strictly controlled substance under national drug scheduling laws and international controls, with no authorized medical use or reimbursement in South Sudan outside of approved clinical research. There is no public record of regulatory approval, licensed clinical programs, or reimbursement for 5‑MeO‑DMT in South Sudan. #

Currently classified as a strictly controlled substance under national drug scheduling laws in most jurisdictions and there is no public record of medical authorization or reimbursement for ibogaine in South Sudan; any access would be limited to approved clinical research or exceptional import/compassionate arrangements, for which no public approvals are documented. #

Because ayahuasca preparations contain DMT (a Schedule I psychotropic substance), there is no documented national authorization or reimbursement pathway for ayahuasca in South Sudan; access would be limited to approved clinical research if permitted. Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research. # #

Mescaline is listed in international schedules (1971 Convention) and there is no public record of national medical authorization or reimbursement for mescaline in South Sudan; as with other classic psychedelics, access would be via approved clinical research only. Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research. # #

Compounds in the 2C family and many substituted phenethylamines are controlled internationally and regionally; there is no evidence of legal medical access or reimbursement for 2C‑X substances in South Sudan and such compounds would be treated as strictly controlled with no authorized medical use outside approved research. Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside approved clinical research. #